OBJECTIVE：To observe therapeutic efficacy and liver toxicity of chemotherapy combined with bevacizumab in the treatment of colorectal cancer liver metastases（CLMs）. METHODS：126 CLMs patients were selected and randomly divided into chemotherapy group（54 cases）and combination group（72 cases）. Chemotherapy group received FOLFOXIRI regimen：irinotecan 165 mg/m2+ oxaliplatin 85 mg/m2+ calcium folinate 200 mg/m2+ fluorouracil 2 g. Combination group was additionally given bevacizumab 5 mg/kg one day before chemotherapy on the basis of FOLFOXIRI regimen. A treatment course of 2 groups lasted for 2 weeks，and both received 12 courses of treatment. The pathological response，survival rate and toxic reactions caused by chemotherapy were compared between 2 groups. RESULTS：Pathological complete response proportion，tumor remission rating（TRG），the proportion of patients with tumor necrosis rate ≥50％ in combination group were significantly higher than chemotherapy group， with statistical significance（P＜0.01）. The proportion of TRG4-5，TRG 1-3 progression-free survival in combination group were significantly higher than chemotherapy group，with statistical significance（P＜0.05）. The incidence of liver parenchymal necrosis in combination group was significantlg higher than chemotherapy group，there was statistical significance（P＞0.05）. CONCLUSIONS： Chemotherapy combined with bevacizumab can improve pathological response and the incidence of CLMs necrosis and doesn’t increase liver toxicity.